Login to Your Account

Orphan endorphins: Add pair to Savara's pipeline with buyout of Serendex

By Randy Osborne
Staff Writer

Monday, June 20, 2016

Savara Pharmaceuticals Inc. CEO Rob Neville told BioWorld Today the all-stock buyout of Serendex Pharmaceuticals A/S brings aboard a pair of orphan products, one of them "already enrolling phase II/III" trials in Europe and Japan for pulmonary alveolar proteinosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription